• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Onsolis (fentanyl buccal)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Onsolis (fentanyl buccal)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Onsolis is an oral transmucosal form of the potent opioid analgesic, fentanyl citrate, a pure opioid agonist whose principal therapeutic action is analgesia. The precise mechanism of the analgesic action is unknown although fentanyl is known to be a mu-opioid receptor agonist. Specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and play a role in the analgesic effects of this drug.

    Onsolis is specifically indicated for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. This product must not be used in opioid non-tolerant patients.

    Onsolis is supplied as a film (200,,400, 600, 800 or 1200 mcg) intended for application to the buccal mucosa (cheek). It utilizes the BioErodible MucoAdhesive (BEMA) bilayer delivery technology which is comprised of water-soluble polymeric films. Onsolis must be individually dose titrated to determine the most effective and tolerable dose.

    Starting Dose:
    All patients MUST begin treatment using one 200 mcg Onsolis film. Patients switching from another oral transmucosal fentanyl product must be started on no greater than 200 mcg.

    • If adequate pain relief is not achieved after one 200 mcg film, titrate using multiples of the 200 mcg film until the patient reaches a dose that provides adequate analgesia with tolerable side effects. Do not use more than four of the 200 mcg Onsolis films simultaneously.
    • If adequate pain relief is not achieved after 800 mcg Onsolis (i.e., four 200 mcg films), and the patient has tolerated the 800 mcg dose, treat the next episode by using one 1200 mcg film. Doses above 1200 mcg Onsolis should not be used.
    • Single doses should be separated by at least 2 hours. Onsolis should only be used once per breakthrough cancer pain episode (it should not be redosed within an episode).
    • During any episode of breakthrough cancer pain, if adequate pain relief is not achieved after Onsolis, rescue medication may be used after 30 minutes as directed by a healthcare provider.

    Clinical Results

    FDA Approval
    The FDA approval of Onsolis was based on the results of a double-blind, placebo-controlled, crossover study. The trial enrolled opioid tolerant adult patients experiencing breakthrough cancer pain but otherwise controlled with maintenance doses of opioid medications. Open-label titration identified a successful dose of Onsolis (adequate analgesia with tolerable side effects), within the range of 200 to 1200 mcg. The primary outcome measure, the mean sum of pain intensity differences at 30 minutes (SPID30) for Onsolis-treated episodes was statistically significantly higher than for placebo-treated episodes.

    Side Effects

    Adverse events associated with the use of Onsolis during dose titration may include, but are not limited to, the following:

    • Nausea
    • Vomiting
    • Dizziness
    • Somnolence

    Adverse events associated with the use of Onsolis during long-term treatment (maintenance periods) may include, but are not limited to, the following:

    • Nausea
    • Vomiting
    • Asthenia
    • Dehydration
    • Dyspnea
    • Fatigue
    • Constipation
    • Dizziness
    • Headache

    Mechanism of Action

    Onsolis is an oral transmucosal form of the potent opioid analgesic, fentanyl citrate, a pure opioid agonist whose principal therapeutic action is analgesia. The precise mechanism of the analgesic action is unknown although fentanyl is known to be a mu-opioid receptor agonist. Specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and play a role in the analgesic effects of this drug.

    Literature References

    Weinstein SM, Messina J, Xie F Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. Cancer 2009 Jun 1;115(11):2571-9

    Darwish M, Kirby M, Jiang JG, Tracewell W, Robertson P Jr Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. Clinical Drug Investigation 2008;28(1):1-7

    Slatkin NE, Xie F, Messina J, Segal TJ Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. The Journal of Supportive Oncology 2007 Jul-Aug;5(7):327-34

    Blick SK, Wagstaff AJ Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer. Drugs 2006;66(18):2387-93

    Portenoy RK, Taylor D, Messina J, Tremmel L A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. The Clinical Journal of Pain 2006 Nov-Dec;22(9):805-11

    Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clinical Therapeutics 2006 May;28(5):707-14

    Additional Information

    For additional information regarding Onsolis or breakthrough cancer pain, please visit the Onsolis web page.

    Approval Date: 2009-07-01
    Company Name: BioDelivery Sciences
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing